South African authorities reported on Thursday a casual link between the death of a patient and the Johnson & Johnson COVID-19 vaccine. This was considered the first death linked to COVID-19 vaccines in the country.
The late patient suffered from rare neurological disorder Guillain-Barre Syndrome shortly after receiving Johnson & Johnson dose.
He was placed on ventilator, and the died.
Professor Hannelie Meyer said in a news conference: “At the time of illness no other cause for the Guillain-Barre Syndrome (GBS) could be identified.”
The personal information of the dead patient including his age was not mentioned in the conference.
Last year, the major European drug regulator, European Medicines Agency (EMA), has found a possible link between Johnson and Johnson (J&J) COVID-19 vaccine, and rare blood clotting.
It added that blood clotting should be mentioned as a possible or a rare side effect of the vaccine, therefore, a warning should be added on J&J vaccine doses labels.
Therefore, the agency asserted that the advantages of the vaccine are higher than the rare possibility of blood clotting.
Last year, a US citizen died and another one was in critical condition after receiving J&J vaccine after suffering from blood clotting complications, according to Food and Drug Administration (FDA).
Until now Six women whose ages wanderer between 18 to 48 years old suffered from rare brain blood clots after receiving the J&J jab.
“One case was fatal, and one patient is in critical condition,” FDA senior member Peter Marks told media agencies.
Therefore, federal advice has recommended suspending using the vaccine after receiving several negative reports from recipients.
Senior Centers for Disease Control and Prevention official Anne Schuchat said: “For people who recently got the vaccine within the last couple of weeks, they should be aware to look for any symptoms.
